Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk

• Published in: Journal of thrombosis and thrombolysis 2007-12, Vol.24 (3), p.283-292
• Main Authors: Shi, Bingxing, Yu, Aiping, Liu, Yuying, Li, Jingchuan, Jin, Jide, Dong, Chunna, Wu, Chutse
• Format: Article
• Language: English
• Subjects: Animals; Anticoagulants - metabolism; Anticoagulants - pharmacology; Blood Coagulation Tests; Disease Models, Animal; Fibrinolytic Agents - metabolism; Fibrinolytic Agents - pharmacology; Hirudins - genetics; Hirudins - isolation & purification; Hirudins - pharmacology; Male; Metalloendopeptidases - genetics; Metalloendopeptidases - isolation & purification; Metalloendopeptidases - pharmacology; Mice; Rats; Recombinant Fusion Proteins - pharmacology; Recombinant Proteins - genetics; Recombinant Proteins - isolation & purification; Recombinant Proteins - pharmacokinetics; Thrombolytic Therapy - methods; Venous Thrombosis - drug therapy
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-007-0036-6

Despite the fact that lytic therapy of thromboembolic disorder has been achieved, reocclusion of the damaged vessels and bleeding complication frequently reduce the therapeutic effect. In order to prevent the vessel reocclusion and enhance the therapeutic effect, combining the anticoagulant with the thrombolytic was assumed. Herein, we propose that restraining but locally releasing anticoagulant activity in the vicinity of thrombus is a way to alleviate the bleeding risk. A bifunctional fusion protein, termed as SFH (Staphylokinase (SAK) linked by FXa recognition peptide at N-terminus of Hirudin (HV)), was designed. SFH retained thrombolytic activity but no anticoagulant activity in thrombus-free blood due to the extension of the N-terminus of HV. However, it could locally liberate intact HV and exhibit anticoagulant activity when FXa or fresh thrombus was present. At equimolar dose, both improved antithrombotic and thrombolytic effects of SFH were observed in kappa-carrageenin inducing mouse-tail thrombosis model and rat inferior vena cava thrombosis model, respectively. Moreover, we observed significantly lower bleeding risk in mice and rats treated with SFH than with the mixture of SAK and HV with monitoring TT (P < 0.01), aPTT (P < 0.05) and PT (P < 0.05), and bleeding time (P < 0.05). In conclusion, SFH is a promising bifunctional therapeutic candidate with lower bleeding risk.